Demographics of the study population*
| Characteristic . | Transplants (N = 1975) . |
|---|---|
| Patient age, median years (range) | 36.8 (0.19-72.4) |
| Donor age, median years (range) | 36.1 (18-61.1) |
| Year of transplantation | |
| 1983-1992 | 74 (4%) |
| 1993-1999 | 548 (28%) |
| 2000-2005 | 880 (45%) |
| 2006-2011 | 436 (22%) |
| Unknown | 37 (2%) |
| Patient-donor sex | |
| Male-male | 762 (39%) |
| Male-female | 397 (20%) |
| Female-male | 433 (22%) |
| Female-female | 366 (19%) |
| Unknown | 17 (<1%) |
| Disease/early, intermediate, late or advanced, other, or unknown† | |
| Acute leukemia | 974 (49%)/325, 347, 251, 51 |
| Chronic myeloid leukemia | 374 (19%)/237, 95, 21, 21 |
| Myelodysplastic syndrome | 241 (12%)/45, 0, 99, 97 |
| Lymphoma | 192 (10%)/ 6, 3, 45, 138 |
| Multiple myeloma | 27 (1%)/ 1, 0, 18, 8 |
| Other malignancies | 12 (<1%), NA |
| Nonmalignancies | 155 (8%), NA |
| Transplant type | |
| Myeloablative/no TBI | 409 (21%) |
| Myeloablative/ TBI | 967 (49%) |
| Reduced-intensity/nonmyeloablative | 482 (24%) |
| Unknown | 117 (6%) |
| Source of cells | |
| Bone marrow | 1157 (59%) |
| eripheral blood stem cells | 779 (39%) |
| Unknown | 39 (2%) |
| GVHD prophylaxis | |
| Any single agent by itself | 42 (2%) |
| Two or more agents mixed together | 1004 (51%) |
| T-cell depletion | 798 (40%) |
| Other combinations | 29 (2%) |
| Missing | 102 (5%) |
| Allele and antigen mismatches | |
| Allele | 389 (20%) |
| Antigen | 1582 (80%) |
| Unknown‡ | 4 (<15) |
| Residue 116 status of the nonshared patient-donor allotypes | |
| Matched | 847 (43%) |
| Mismatched | 1108 (56%) |
| Unknown | 20 (<1%) |
| Residue 77/80 status of the nonshared patient-donor allotypes | |
| Matched | 955 (48%) |
| Mismatched | 996 (50%) |
| Unknown | 24 (1%) |
| Characteristic . | Transplants (N = 1975) . |
|---|---|
| Patient age, median years (range) | 36.8 (0.19-72.4) |
| Donor age, median years (range) | 36.1 (18-61.1) |
| Year of transplantation | |
| 1983-1992 | 74 (4%) |
| 1993-1999 | 548 (28%) |
| 2000-2005 | 880 (45%) |
| 2006-2011 | 436 (22%) |
| Unknown | 37 (2%) |
| Patient-donor sex | |
| Male-male | 762 (39%) |
| Male-female | 397 (20%) |
| Female-male | 433 (22%) |
| Female-female | 366 (19%) |
| Unknown | 17 (<1%) |
| Disease/early, intermediate, late or advanced, other, or unknown† | |
| Acute leukemia | 974 (49%)/325, 347, 251, 51 |
| Chronic myeloid leukemia | 374 (19%)/237, 95, 21, 21 |
| Myelodysplastic syndrome | 241 (12%)/45, 0, 99, 97 |
| Lymphoma | 192 (10%)/ 6, 3, 45, 138 |
| Multiple myeloma | 27 (1%)/ 1, 0, 18, 8 |
| Other malignancies | 12 (<1%), NA |
| Nonmalignancies | 155 (8%), NA |
| Transplant type | |
| Myeloablative/no TBI | 409 (21%) |
| Myeloablative/ TBI | 967 (49%) |
| Reduced-intensity/nonmyeloablative | 482 (24%) |
| Unknown | 117 (6%) |
| Source of cells | |
| Bone marrow | 1157 (59%) |
| eripheral blood stem cells | 779 (39%) |
| Unknown | 39 (2%) |
| GVHD prophylaxis | |
| Any single agent by itself | 42 (2%) |
| Two or more agents mixed together | 1004 (51%) |
| T-cell depletion | 798 (40%) |
| Other combinations | 29 (2%) |
| Missing | 102 (5%) |
| Allele and antigen mismatches | |
| Allele | 389 (20%) |
| Antigen | 1582 (80%) |
| Unknown‡ | 4 (<15) |
| Residue 116 status of the nonshared patient-donor allotypes | |
| Matched | 847 (43%) |
| Mismatched | 1108 (56%) |
| Unknown | 20 (<1%) |
| Residue 77/80 status of the nonshared patient-donor allotypes | |
| Matched | 955 (48%) |
| Mismatched | 996 (50%) |
| Unknown | 24 (1%) |
NA, not applicable.
Other malignancies included breast cancer, renal/kidney carcinoma, hepatoblastoma. Nonmalignancies included severe aplastic anemia, Shwachman-Diamond anemia, Diamond-Blackfan anemia, adrenoleukodystrophy, Wiskott Aldrich syndrome, hyper IgM syndrome, hemoglobinopathy, chronic granulomatous disease, familial erythro hemophagocytic lymphocytosis, paroxysmal nocturnal hemoglobinuria, metachromatic leukodystrophy, immunodysregulation polyendocrinopathy enteropathy X-linked like syndrome, Fanconi anemia, bone marrow aplasia, idiopathic bone marrow failure, sickle cell disease, immune deficiency disorder, thalassemia, inherited abnormalities of erythrocyte differentiation or function, other immune system disorders, inherited abnormality of platelets, inherited disorder of metabolism, histiocytic disorders and other nonmalignancies.
Additional characteristics are provided in supplemental Table 2.
Disease status prior to transplant is categorized as early (first complete remission [CR] of acute myeloid leukemia [AML] or acute lymphoblastic leukemia [ALL]; first chronic phase [CP] of CML; refractory anemia [RA]; refractory anemia with ring sideroblasts of myelodysplastic syndrome [MDS]; non-Hodgkin lymphoma in first CR; chronic lymphoid leukemia in CR); intermediate (second or higher CR of AML or ALL; second or higher CP or accelerated phase of CML; Hodgkin lymphoma in third CR); late or advanced (primary induction failure or first or higher relapse of AML or ALL; blast phase of CML; MDS RA with excess blasts or excess blasts in transformation; non-Hodgkin lymphoma in relapse; Hodgkin lymphoma in third relapse; myeloma; unnamed MDS or unknown).
Four individuals each encoded novel HLA-C sequences that have not yet been characterized using serological reagents.